Alzheimer Disease

Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

The National Institutes of Health grants each entity $14.8 million in funding over the course of 5 years to conduct research into the progressive disease.

The FDA's green light for the Alzheimer medication is worrisome, as clinical trials proved inconclusive.

It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.